Sign In
Buy SNY
$43.98
-0.680 (-1.52%)
At Close: Jul 20, 2026
Sanofi and Regeneron's Dupixent approved in the US as the first biologic medicine for young children with uncontrolled chronic spontaneous urticaria
Press Release: Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children
01:05am, Wednesday, 22'nd Apr 2026
Sanofi's Tzield approved in the US to delay the onset of stage 3 type 1 diabetes in young children Expanded approval includes children aged one year and above with stage 2 T1D to delay the onset of st
Press Release: Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US
01:00am, Wednesday, 22'nd Apr 2026
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US Paris, April 22, 2026. The US Food and Drug Administration (FDA) has extended by up to three months the target a
What To Expect From Sanofi In Q1 2026
09:28am, Monday, 20'th Apr 2026
On April 23, Sanofi will report its results for the first quarter of 2026. As a reminder, its revenue grew 23.1% year-over-year to $13.53 billion in Q4 last year. Meanwhile, Sanofi's non-GAAP P/E rati
Assetmark Inc. Purchases 86,496 Shares of Sanofi $SNY
03:26am, Thursday, 16'th Apr 2026
Assetmark Inc. boosted its position in Sanofi (NASDAQ: SNY) by 24.2% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
Sanofi (SNY) to Release Earnings on Thursday
01:20am, Thursday, 16'th Apr 2026
Sanofi (NASDAQ: SNY - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect Sanofi to post earnings of $0.9330 per share and reve
Stock Market Today (LIVE): PPI Beats Fear, But Oil Risks Loom; Novo's OpenAI Deal Lifts Shares
09:33am, Tuesday, 14'th Apr 2026
Top insights from the latest market news from Tuesday, April 14, from The Motley Fool analysts on Team Rule Breakers and Team Hidden Gems.
SNY & REGN's Dupixent Gets EU Approval for Pediatric Use in Urticaria
10:46am, Monday, 13'th Apr 2026
Sanofi wins EC nod to expand Dupixent use to children aged 2 to 11 years with CSU, backed by phase III data, marking the first targeted option in the EU.
Sanofi and Regeneron's Dupixent approved in the EU as the first targeted medicine to treat young children with chronic spontaneous urticaria
SNY's Lunsekimig Succeeds in Asthma & CRSwNP Studies, Fails in Eczema
01:01pm, Tuesday, 07'th Apr 2026
Sanofi posts strong mid-stage results for lunsekimig in asthma and CRSwNP but a setback in atopic dermatitis clouds the broader clinical picture.
Press Release: Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP
01:00am, Tuesday, 07'th Apr 2026
Sanofi's lunsekimig met primary and key secondary endpoints in phase 2 respiratory studies in asthma and CRSwNP The AIRCULES phase 2b study achieved its primary and key secondary endpoints in mod
Aberdeen Group plc Buys 86,314 Shares of Sanofi $SNY
03:08am, Monday, 06'th Apr 2026
Aberdeen Group plc lifted its stake in shares of Sanofi (NASDAQ: SNY) by 22.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 467,2
Sanofi Gets EU Nod for Rezurock in Chronic Graft-Vs-Host Disease
01:16pm, Tuesday, 31'st Mar 2026
SNY secures EU conditional approval for Rezurock to treat chronic GVHD in adults and children aged 12 years and older.
Euro Pacific Asset Management LLC Takes Position in Sanofi $SNY
05:04am, Tuesday, 31'st Mar 2026
Euro Pacific Asset Management LLC acquired a new stake in shares of Sanofi (NASDAQ: SNY) during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Com
Press Release: Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease
01:00am, Tuesday, 31'st Mar 2026
Sanofi's Rezurock approved in the EU to treat chronic graft-vs-host disease Rezurock is now approved in the EU for adults and children aged 12 years and older with chronic GVHD, providing a new medici
